Compare Abbott Laboratories (ABT) vs Halliburton Company (HAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Halliburton Company — how do they compare? Abbott Laboratories trades at $95.66 (market cap $166.94B), while Halliburton Company trades at $34.81 (market cap $28.23B). The key difference: Abbott Laboratories is far larger — about 5.9× Halliburton Company's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | HAL | |
|---|---|---|
Market Cap | $166.94B | $28.23B |
Sector | Health | Energy |
52-Week High | $136.62 | $42.98 |
52-Week Low | $82.57 | $20.50 |
Enterprise Value | $193.69B | $34.31B |
Dividend Yield | 2.63% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Halliburton (HAL) trades at $33.79, up 2.52% today, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a P/E of 18.23 and ROE of 14.56%, though 2025 revenue declined to $22.18B. Recent news highlights digital transformation partnerships and upcoming Q2 2026 earnings, while analyst consensus remains strongly bullish with a $44.22 price target.
HAL presents a compelling value opportunity with 30% upside to consensus target, supported by consistent earnings outperformance and strategic digital initiatives. Key risks include oil price volatility and competitive pressures in energy services. The stock's current discount to analyst targets and strong institutional support suggest potential for recovery despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
